Overview

Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.

Status:
NOT_YET_RECRUITING

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

To assess the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (with symptomatic dysphagia or oligometastatic disease)，and to evaluate the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (without symptomatic dysphagia or oligometastatic disease).

Phase:

PHASE2

Details

Lead Sponsor:

The First Affiliated Hospital of Henan University of Science and Technology

Treatments:

apatinib
Radiotherapy